Compare Danaher Corporation (DHR) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs SkyWest Inc — how do they compare? Danaher Corporation trades at $205.12 (market cap $145.83B), while SkyWest Inc trades at $106.37 (market cap $4.19B). The key difference: Danaher Corporation is far larger — about 34.8× SkyWest Inc's market cap, and Danaher Corporation pays a 0.77% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| DHR | SKYW | |
|---|---|---|
Market Cap | $145.83B | $4.19B |
Sector | Health | Technology |
52-Week High | $242.05 | $123.72 |
52-Week Low | $161.91 | $78.40 |
Enterprise Value | $168.04B | $5.97B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
SkyWest (SKYW) trades at $106.38, down 1.2% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $109.33. The stock shows solid fundamentals with a P/E of 10.72 and ROE of 15.34%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales alongside institutional interest and a 7.7% post-earnings rally noted by Zacks Investment Research on 2026-07-27.
The outlook is cautiously positive given analyst buy ratings (56.25%) and undervalued metrics, but risks include fuel cost volatility from Iran war impacts (New York Post, 2026-07-07) and mixed earnings performance. Upside potential exists if Q3 2026 meets its $3.13 EPS expectation, balancing insider selling with buyback support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
